Preclinical study of deactivated platelets describes promising new approach to treating diseases
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published today in Science Translational Medicine.
The therapeutic approach involves modifying human platelets to create "decoys" that are still capable of binding to some cells but will not aggregate or carry out the other normal platelet functions, including chemical signaling associated with the clotting process.
"The reversibility and immediate onset of action are major advantages of our platelet decoys, and we envision them to be useful in hospital-based situations," Anne-Laure Papa, an assistant professor of biomedical engineering at the George Washington University, said. Dr. Papa was a postdoctoral fellow at Harvard University's Wyss Institute when the research was conducted. "The therapy could prevent clotting in high-risk patients just before they undergo surgery, or be given to cancer patients alongside chemotherapy to prevent existing tumors from spreading."
Platelets play a vital role in halting bleeding and help protect against minor and life-threatening bleeding. However, hyperactive platelets can also contribute to various disorders, including severe blood clots, heart disease and cancer. While several antiplatelet drugs fight clots, their effects are not easily reversible, leaving patients vulnerable if they develop unexpected severe bleeding or are in need of an emergency surgical procedure.
Platelets also play an important part in cancer metastasis by binding to tumor cells and protecting them both from the body's immune system and shear stress as they circulate in the bloodstream. Platelets may also help the cancer cells exit through blood vessels and seed distant tissues during the process of metastasis.
To create the decoy platelets, the research team used a detergent treatment and centrifugation to strip natural human platelets of their inner structures and remove their basic activation and aggregation abilities. These decoy platelets became about one-third the size of a regular platelet while retaining a majority of adhesion receptors on their surface. This allows them to bind to other cells in the bloodstream, such as cancer cells, but not become active during the blood clotting process.
The researchers, led by Dr. Papa and Donald E. Ingber, the director of the Wyss Institute at Harvard University, first examined how the decoys might impede the formation of blood clots. The team injected the decoys into a microfluidic blood-vessel-mimicking device and observed how the decoys reacted to various platelet-stimulating chemicals. The researchers found the decoys did not show typical clotting behaviors, and when added to human blood within the device, the normal platelets showed a reduced ability to aggregate and create a clot by binding to the vessel's walls.
In addition, the researchers quickly reversed the effects of the decoys on normal platelets by introducing fresh platelets into the blood.
"Our ability to reverse the platelet inhibiting effects with a simple reintroduction of normal platelets is very encouraging as currently available anti-platelet agents are often difficult to reverse in emergency settings such as severe bleeding," Dr. Papa said.
Based on the key role platelets play in supporting cancer metastasis in the bloodstream, the team sought to target circulating tumor cells with their cellular approach. The decoy platelets were able to compete with normal platelets when binding to cancer cells and were effective in preventing cancer cell extrusion out of a vasculature-emulating microfluidic chip model. Furthermore, in a model of metastasis, there was a significant reduction in the burden of established metastatic tumors when cancer cells were introduced simultaneously with platelets and decoys.
In the future, the researchers will continue to work on this technology to enhance circulation time in comparison to platelets. They also hope to study whether platelet decoys can be used as drug transporters to target platelet-related conditions in the body.
Timothy Pierce | EurekAlert!
To proliferate or not to proliferate
21.03.2019 | Max-Planck-Institut für molekulare Zellbiologie und Genetik
Discovery of a Primordial Metabolism in Microbes
21.03.2019 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Nano- and microtechnology are promising candidates not only for medical applications such as drug delivery but also for the creation of little robots or flexible integrated sensors. Scientists from the Max Planck Institute for Polymer Research (MPI-P) have created magnetic microparticles, with a newly developed method, that could pave the way for building micro-motors or guiding drugs in the human body to a target, like a tumor. The preparation of such structures as well as their remote-control can be regulated using magnetic fields and therefore can find application in an array of domains.
The magnetic properties of a material control how this material responds to the presence of a magnetic field. Iron oxide is the main component of rust but also...
Due to the special arrangement of its molecules, a new coating made of corn starch is able to repair small scratches by itself through heat: The cross-linking via ring-shaped molecules makes the material mobile, so that it compensates for the scratches and these disappear again.
Superficial micro-scratches on the car body or on other high-gloss surfaces are harmless, but annoying. Especially in the luxury segment such surfaces are...
The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.
A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...
Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have proposed a way to create a completely new source of radiation. Ultra-intense light pulses consist of the motion of a single wave and can be described as a tsunami of light. The strong wave can be used to study interactions between matter and light in a unique way. Their research is now published in the scientific journal Physical Review Letters.
"This source of radiation lets us look at reality through a new angle - it is like twisting a mirror and discovering something completely different," says...
New research group at the University of Jena combines theory and experiment to demonstrate for the first time certain physical processes in a quantum vacuum
For most people, a vacuum is an empty space. Quantum physics, on the other hand, assumes that even in this lowest-energy state, particles and antiparticles...
11.03.2019 | Event News
01.03.2019 | Event News
28.02.2019 | Event News
21.03.2019 | Life Sciences
21.03.2019 | Physics and Astronomy
21.03.2019 | HANNOVER MESSE